Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | SCN1A | P35498 | 3/20 | 0.53 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.53 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11807946 | 0.86 | ALDH1A1 (0.74) | ALDH1A1KDM4ELMNASCN1ASCN2A | |
| Hydrochloric Acid SCHEMBL11672178 | 0.86 | ALDH1A1 (0.65) | ALDH1A1KDM4ELMNASCN1ASCN2A | |
| SCHEMBL2469904 | 0.86 | LMNA (0.69) | ALDH1A1KDM4ELMNASCN1ASCN2A | |
| SCHEMBL11338177 | 0.85 | ALDH1A1 (0.76) | ALDH1A1KDM4ELMNASCN1ASCN2A | |
| SCHEMBL7956961 | 0.85 | ALDH1A1 (0.58) | ALDH1A1KDM4EHSP90AA1MAPTHTT | |
| Hydrochloric Acid SCHEMBL11671640 | 0.84 | ALDH1A1 (0.74) | ALDH1A1KDM4ELMNASCN1ASCN2A | |
| SCHEMBL8340067 | 0.84 | LMNA (0.70) | ALDH1A1KDM4ELMNASCN1ASCN2A | |
| SCHEMBL11339945 | 0.83 | ALDH1A1 (0.62) | ALDH1A1KDM4ELMNASCN1ASCN2A | |
| SCHEMBL536427 | 0.83 | MAPT (0.59) | ALDH1A1KDM4ELMNAHSP90AA1MAPT | |
| SCHEMBL11340276 | 0.82 | TSHR (0.62) | ALDH1A1KDM4ELMNASCN1ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11022604-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2021-06-01 | — | — | US | disclosed |
| US-11022604-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2020-02-27 | — | — | US | disclosed |
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2020-02-27 | — | — | US | disclosed |
| US-8101625-B2 | Pyrimidinones as Casein Kinase II (CK2) modulators | EXELIXIS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-1948617-B1 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS INC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20090215803-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | EXELIXIS, INC. | 2009-08-27 | — | — | US | disclosed |
| EP-1948617-A2 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | Exelixis, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007048065-A2 | PYRIMIDINONES AS CASEIN KINASE II (CK2) MODULATORS | EXELIXIS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200064334-A1 | Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof | ILK, LRRC47, RPL37 | ALDH1A1 1721/4885KDM4E 3638/4885LMNA 174/4885 |
| US-11022604-B2 | Dock derived compound against laminin receptor (37 LR) and uses thereof | ILK, LRRC47, RPL37 | ALDH1A1 1721/4885KDM4E 3638/4885LMNA 174/4885 |
| US-20090215803-A1 | Pyrimidinones as Casein Kinase II (CK2) Modulators | CSNK2A1, CSNK1A1, CSNK2A2 | ALDH1A1 3986/4885KDM4E 1821/4885LMNA 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.